Meeting HighlightsVideo

VIDEO: SGLT inhibitors for type 1 diabetes require more study

LOS ANGELES — In this video exclusive, Mohammad El-rifai, MD, an endocrinologist at Cheyenne Regional Medical Center, describes the benefits and risks of using SGLT inhibitors in type 1 diabetes.

Although these agents have received interest as possible adjunctive therapies to insulin for type 1 diabetes, SGLT2 inhibitors and a dual SGLT1/SGLT2 inhibitor have not been approved for use in this population, primarily because of concerns about diabetic ketoacidosis.

Watch the video for more.

LOS ANGELES — In this video exclusive, Mohammad El-rifai, MD, an endocrinologist at Cheyenne Regional Medical Center, describes the benefits and risks of using SGLT inhibitors in type 1 diabetes.

Although these agents have received interest as possible adjunctive therapies to insulin for type 1 diabetes, SGLT2 inhibitors and a dual SGLT1/SGLT2 inhibitor have not been approved for use in this population, primarily because of concerns about diabetic ketoacidosis.

Watch the video for more.

    See more from American Association of Clinical Endocrinologists Annual Meeting